Cancer drug tested in people with liver damage

NCT ID NCT07144111

Recruiting now Knowledge-focused Sponsor: Genentech, Inc. Source: ClinicalTrials.gov ↗

Summary

This study is testing how liver problems affect how the body processes a single dose of the cancer drug inavolisib. Researchers will compare people with moderate or severe liver impairment to healthy people with normal liver function. The goal is to understand if liver problems change how much drug stays in the body and how safe it is for these patients.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATIC IMPAIRMENT are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Orange County Research Center
RECRUITING

Lake Forest, California, 92630, United States
Orlando Clinical Research Center
RECRUITING

Orlando, Florida, 32809, United States
Pinnacle Clinical Research - San Antonio
RECRUITING

San Antonio, Texas, 78229, United States
The Texas Liver Institute, Inc.
RECRUITING

San Antonio, Texas, 78215, United States

Conditions

Explore the condition pages connected to this study.

HEPATIC IMPAIRMENT